Stocks saw a pre-trade increase of 4% on Thursday, following an emergency approval request by Regeneron for REGN-COV2, the experimental antibody cocktail used in President Trump’s recent COVID-19 treatment. Trump’s symptoms seem to have subsided in record time and he recently spoke of Regeneron as a “cure,” although there is no medical or scientific verification of his claim.
REGN-COV2 works with a combination of two antibodies which were specifically designed to block the coronavirus infection that causes COVID-19. The company said they have around 50,000 doses ready for patient treatment and expect that number to increase to 300,000 over the next several months.
The biotechnology company stated if the Food and Drug Administration approves its use, they will make the REGN-COV2 dual-monoclonal antibody therapy available at no cost to American’s and will take responsibility for its distribution. Regeneron recently formed a partnership with multi-national Swiss health care company Roche to meet the anticipated global demand.
Although it has yet to be approved by the FDA, doctors administered an 8-gram dose of the treatment early in Trump’s diagnosis. Regeneron said their pre-clinical studies showed a reduction in the infection severity and lung damage in primates used for the trail experiments.
Ann Sullivan is a contributing staff writer covering national and world news topics. She brings dedicated experience having written international and domestic news, blogs, and web content for over 20 years. She’s also a published poet and graphic designer with degrees in Business and Graphic Communications and has been a music distributor, music industry sponsorship sales director and band manager.